大鼠体内螺内酯向坎利酮的转化以及螺内酯和坎利酸钾的处置动力学 - Suppr

Suppr

超能文献

Conversion of spironolactone to canrenone and disposition kinetics of spironolactone and canrenoate-potassium in rats.

作者信息

Sadée W, Abshagen U, Finn C, Rietbrock N

出版信息

Naunyn Schmiedebergs Arch Pharmacol. 1974;283(3):303-18. doi: 10.1007/BF00499190.

DOI:10.1007/BF00499190

PMID:4276758

Abstract

摘要

相似文献

Conversion of spironolactone to canrenone and disposition kinetics of spironolactone and canrenoate-potassium in rats.大鼠体内螺内酯向坎利酮的转化以及螺内酯和坎利酸钾的处置动力学

Naunyn Schmiedebergs Arch Pharmacol. 1974;283(3):303-18. doi: 10.1007/BF00499190.

Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.

J Pharmacol Exp Ther. 1973 Jun;185(3):686-95.

Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.螺内酯、坎利酮及其共同代谢产物坎利酮对 Dimension Vista 地高辛检测的影响。

J Clin Lab Anal. 2010;24(6):413-7. doi: 10.1002/jcla.20421.

Spironolactone metabolism in man studied by gas chromatography-mass spectrometry.

Drug Metab Dispos. 1975 Nov-Dec;3(6):467-78.

Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.雅培 ARCHITECT 临床化学和免疫分析系统：地高辛检测不受螺内酯、坎利酮及其常见代谢产物坎利酮的干扰。

Ther Drug Monit. 2011 Feb;33(1):128-31. doi: 10.1097/FTD.0b013e3181fd4c30.

Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.螺内酯、坎利酸钾及其共同代谢产物坎利酮对采用新型地高辛免疫分析法地高辛III测定血清地高辛的影响。

Ther Drug Monit. 2008 Dec;30(6):744-7. doi: 10.1097/FTD.0b013e31818b0e6a.

Biotransformation of the mineralocorticoid receptor antagonists spironolactone and canrenone by human CYP11B1 and CYP11B2: Characterization of the products and their influence on mineralocorticoid receptor transactivation.盐皮质激素受体拮抗剂螺内酯和坎利酮在人CYP11B1和CYP11B2作用下的生物转化：产物表征及其对盐皮质激素受体反式激活的影响

J Steroid Biochem Mol Biol. 2016 Oct;163:68-76. doi: 10.1016/j.jsbmb.2016.04.004. Epub 2016 Apr 25.

Spironolactone. I. Disposition and metabolism.

Clin Pharmacol Ther. 1976 Feb;19(2):158-69. doi: 10.1002/cpt1976192158.

[Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].苄氟噻嗪与螺内酯联合应用的药代动力学研究及生物利用度

Arzneimittelforschung. 1986 Mar;36(3):490-5.

Effect of spironolactone and its metabolites on contractile property of isolated rat aorta rings.螺内酯及其代谢产物对离体大鼠主动脉环收缩特性的影响。

J Cardiovasc Pharmacol. 2000 Aug;36(2):230-5. doi: 10.1097/00005344-200008000-00013.

引用本文的文献

Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.螺内酯通过拮抗海蟾蜍毒素减轻实验性尿毒症心肌病。

Hypertension. 2009 Dec;54(6):1313-20. doi: 10.1161/HYPERTENSIONAHA.109.140038. Epub 2009 Nov 2.

Difference in metabolic profile of potassium canrenoate and spironolactone in the rat: mutagenic metabolites unique to potassium canrenoate.

Arch Toxicol. 1988 Jan;61(3):201-12. doi: 10.1007/BF00316635.

Pharmacokinetics of spironolactone in man.螺内酯在人体中的药代动力学。

Naunyn Schmiedebergs Arch Pharmacol. 1976 Dec;296(1):37-45. doi: 10.1007/BF00498838.

Metabolism of digitoxin in man and its modification by spironolactone.洋地黄毒苷在人体内的代谢及其受螺内酯的影响。

Eur J Clin Pharmacol. 1976 Mar 22;09(5-6):345-54. doi: 10.1007/BF00606547.

Effects of pretreatment with spironolactone of pharmacokinetics of 4'''-methyldigoxin in man.螺内酯预处理对人4'''-甲基地高辛药代动力学的影响。

Naunyn Schmiedebergs Arch Pharmacol. 1976;292(1):87-92. doi: 10.1007/BF00506494.

Canrenoate disposition in dogs. Tissue distribution and elimination.犬体内烯睾丙酸钾的处置。组织分布与消除。

Naunyn Schmiedebergs Arch Pharmacol. 1977 Jun;298(2):181-7. doi: 10.1007/BF00508627.

Non-interaction of spironolactone medication and cortisol metabolism in man.螺内酯药物与人皮质醇代谢之间无相互作用。

Klin Wochenschr. 1978 Feb 1;56(3):135-8. doi: 10.1007/BF01478568.

Effect of entekohepatic circulation on the pharmacokinetics of spironolactone in man.肝肠循环对螺内酯在人体内药代动力学的影响。

Naunyn Schmiedebergs Arch Pharmacol. 1977 Nov;300(3):281-7. doi: 10.1007/BF00500971.

Improved method for comparative evaluation of aldosterone antagonists in healthy man.健康男性中醛固酮拮抗剂比较评估的改进方法

Eur J Clin Pharmacol. 1977 Dec 2;12(4):247-55. doi: 10.1007/BF00607423.

本文引用的文献

Blocking the renal electrolyte effects of mineralocorticoids with an orally active steroidal spirolactone.用口服活性甾体螺内酯阻断盐皮质激素的肾脏电解质效应。

Endocrinology. 1960 Jul;67:125-32. doi: 10.1210/endo-67-1-125.

[TUBULAR EFFECTS AND RENAL ELIMINATION OF SPIROLACTONES].[螺内酯的肾小管效应及肾脏排泄]

Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1964 Jun 11;247:419-28.

[ON THE METABOLISM OF 3-(3-OXO-7-ALPHA-ACETYLTHIO-17-BETA-HYDROXY-4-ANDROSTEN-17-ALPHA-YL)-PROPIONIC ACID-GAMMA-LACTONE].[关于3-(3-氧代-7-α-乙酰硫基-17-β-羟基-4-雄甾烯-17-α-基)-丙酸-γ-内酯的代谢]

Arzneimittelforschung. 1963 Nov;13:972-7.

PHARMACOLOGICAL PROPERTIES OF A MINERALOCORTICOID ANTAGONIST (SC-14266).一种盐皮质激素拮抗剂（SC - 14266）的药理学特性

Arch Int Pharmacodyn Ther. 1964 May 1;149:8-24.

RELATIONSHIP OF PLASMA ALDADIENE LEVELS AND ANTIMINERALOCORTICOID EFFECTS OF SPIRONOLACTONE IN THE LABORATORY.实验室中血浆醛二烯水平与螺内酯抗盐皮质激素作用的关系。

Proc Soc Exp Biol Med. 1964 Mar;115:837-40. doi: 10.3181/00379727-115-29052.

Pharmacokinetic and metabolic fate of potassium canrenoate (SC-14266) in man.安体舒通钾（SC - 14266）在人体中的药代动力学及代谢转归

J Pharm Sci. 1971 May;60(5):708-15. doi: 10.1002/jps.2600600510.

Disposition of tritium-labeled spirolactones in the dog.

J Pharm Sci. 1972 Jul;61(7):1132-5. doi: 10.1002/jps.2600610721.

Plasma levels of spirolactones in the dog.犬体内螺内酯的血浆水平。

J Pharm Sci. 1972 Jul;61(7):1129-32. doi: 10.1002/jps.2600610720.

Fluorometric microassay for spironolactone and its metabolites in biological fluids.生物流体中螺内酯及其代谢物的荧光微量测定法。

J Pharm Sci. 1972 Jul;61(7):1126-9. doi: 10.1002/jps.2600610719.

Isolation and identification of novel sulfur-containing metabolites of spironolactone (Aldactone).螺内酯（安体舒通）新型含硫代谢物的分离与鉴定。

Steroids. 1972 Jul;20(1):41-62. doi: 10.1016/0039-128x(72)90117-1.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验